假说：血管紧张素转换酶抑制剂和血管紧张素受体阻滞剂可能会增加 COVID-19 重症风险。
Hypothesis: angiotensin-converting enzyme inhibitors and angiotensin receptor blockers may increase the risk of severe COVID-19.
机构信息
Environmental and Occupational Health Sciences, School of Public Health; Professor of Anesthesiology, School of Medicine, Louisiana State University Health Sciences Center, 2020 Gravier Street New Orleans, Louisiana 70112 USA.
出版信息
J Travel Med. 2020 May 18;27(3). doi: 10.1093/jtm/taaa041.
Abstract
Intravenous infusions of angiotensin-converting enzyme inhibitors (ACEIs) and angiotensin receptor blockers (ARBs) in experimental animals increase the numbers of angiotensin-converting enzyme 2 (ACE2) receptors in the cardiopulmonary circulation. ACE2 receptors serve as binding sites for SARS-CoV-2 virions in the lungs. Patients who take ACEIs and ARBS may be at increased risk of severe disease outcomes due to SARS-CoV-2 infections.
摘要
在实验动物中静脉输注血管紧张素转换酶抑制剂（ACEIs）和血管紧张素受体阻滞剂（ARBs）会增加心肺循环中血管紧张素转换酶 2（ACE2）受体的数量。ACE2 受体是肺部 SARS-CoV-2 病毒颗粒的结合位点。服用 ACEIs 和 ARBs 的患者可能由于 SARS-CoV-2 感染而面临更严重疾病后果的风险增加。
相似文献
1
Hypothesis: angiotensin-converting enzyme inhibitors and angiotensin receptor blockers may increase the risk of severe COVID-19.
J Travel Med. 2020 May 18;27(3). doi: 10.1093/jtm/taaa041.
2
A Meta-analysis of the Relationship Between Renin-Angiotensin-Aldosterone System Inhibitors and COVID-19.
Am J Cardiol. 2020 Sep 1;130:159-161. doi: 10.1016/j.amjcard.2020.05.038. Epub 2020 Jun 2.
3
COVID-19 and Angiotensin-Converting Enzyme Inhibitors and Angiotensin Receptor Blockers: What Is the Evidence?
JAMA. 2020 May 12;323(18):1769-1770. doi: 10.1001/jama.2020.4812.
4
COVID-19: The heart of the issue.
J Card Surg. 2020 Aug;35(8):2112. doi: 10.1111/jocs.14684. Epub 2020 Jun 16.
5
Cardiovascular disease and the impact of COVID-19.
J Card Surg. 2020 Aug;35(8):2113. doi: 10.1111/jocs.14682. Epub 2020 Jun 16.
6
COVID-19 and cardiovascular disease: What we know, what we think we know, and what we need to know.
J Mol Cell Cardiol. 2020 Jul;144:12-14. doi: 10.1016/j.yjmcc.2020.04.026. Epub 2020 Apr 24.
7
8
Coronavirus Disease 2019 (COVID-19): Do Angiotensin-Converting Enzyme Inhibitors/Angiotensin Receptor Blockers Have a Biphasic Effect?
J Am Heart Assoc. 2020 Apr 7;9(7):e016509. doi: 10.1161/JAHA.120.016509. Epub 2020 Apr 1.
9
Angiotensin-converting enzyme inhibitors and angiotensin receptor blockers may be harmful in patients with diabetes during COVID-19 pandemic.
Diabetes Metab Syndr. 2020 Jul-Aug;14(4):349-350. doi: 10.1016/j.dsx.2020.04.019. Epub 2020 Apr 15.
10
Facts and reflections on COVID-19 and anti-hypertensives drugs.
Drug Discov Ther. 2020 May 6;14(2):105-106. doi: 10.5582/ddt.2020.01017. Epub 2020 Mar 26.
引用本文的文献
1
Angiotensin-Converting Enzyme Inhibition and/or Angiotensin Receptor Blockade Modulate Cytokine Profiles and Improve Clinical Outcomes in Experimental COVID-19 Infection.
Int J Mol Sci. 2025 Aug 8;26(16):7663. doi: 10.3390/ijms26167663.
2
Therapeutic Approaches for COVID-19: A Review of Antiviral Treatments, Immunotherapies, and Emerging Interventions.
Adv Ther. 2025 May 8. doi: 10.1007/s12325-025-03218-3.
3
Unveiling the Interplay-Vitamin D and ACE-2 Molecular Interactions in Mitigating Complications and Deaths from SARS-CoV-2.
Biology (Basel). 2024 Oct 16;13(10):831. doi: 10.3390/biology13100831.
4
Lisinopril increases lung ACE2 levels and SARS-CoV-2 viral load and decreases inflammation but not disease severity in experimental COVID-19.
Front Pharmacol. 2024 Jul 12;15:1414406. doi: 10.3389/fphar.2024.1414406. eCollection 2024.
5
A Focus on the Pathophysiology of Adrenomedullin Expression: Endothelitis and Organ Damage in Severe Viral and Bacterial Infections.
Cells. 2024 May 22;13(11):892. doi: 10.3390/cells13110892.
6
Role of renin-angiotensin system/angiotensin converting enzyme-2 mechanism and enhanced COVID-19 susceptibility in type 2 diabetes mellitus.
World J Diabetes. 2024 Apr 15;15(4):606-622. doi: 10.4239/wjd.v15.i4.606.
7
A comprehensive review on pharmacologic agents, immunotherapies and supportive therapeutics for COVID-19.
Narra J. 2022 Dec;2(3):e92. doi: 10.52225/narra.v2i3.92. Epub 2022 Dec 8.
8
Pathological Interplay and Clinical Complications between COVID-19 and Cardiovascular Diseases: An Overview in 2023.
Cardiology. 2024;149(1):60-70. doi: 10.1159/000533359. Epub 2023 Aug 16.
9
COVID-19-Triggered Acute Liver Failure and Rhabdomyolysis: A Case Report and Review of the Literature.
Viruses. 2023 Jun 27;15(7):1445. doi: 10.3390/v15071445.
10
Potential Drugs in COVID-19 Management.
Curr Med Chem. 2024;31(22):3245-3264. doi: 10.2174/0929867331666230717154101.
Zotero 插件